Effectiveness of MF59™-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly

This publication has 35 references indexed in Scilit:

• MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complications
  Vaccine, 2007
• New Generation Vaccine Adjuvants
  Published by Wiley ,2007
• Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34 892 subjects
  European Heart Journal, 2007
• Influenza‐Associated Mortality in Hong Kong
  Clinical Infectious Diseases, 2004
• Influenza-Associated Hospitalizations in the United States
  JAMA, 2004
• Influenza and the Winter Increase in Mortality in the United States, 1959-1999
  American Journal of Epidemiology, 2004
• Influenza
  The Lancet, 2003
• A New MF59-Adjuvanted Influenza Vaccine Enhances the Immune Response in the Elderly with Chronic Diseases: Results from an Immunogenicity Meta-Analysis
  Gerontology, 2003
• Ageing and infection
  The Lancet Infectious Diseases, 2002
• Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
  Vaccine, 1999